Alunbrig
Named-patient access overview. Alunbrig is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Alunbrig (brigatinib) is an oral, once-daily second-generation anaplastic lymphoma kinase (ALK) inhibitor developed approximately by Takeda Oncology, with US FDA approval in 2017 (accelerated) and full approval in 2020 for ALK-positive metastatic non-small cell lung cancer (NSCLC). It is one of the small set of ALK inhibitors used as first-line or post-crizotinib therapy and has clinical evidence supporting CNS activity for brain-metastatic ALK-positive disease. For a Kuwait family weighing this option, the practical question is rarely whether brigatinib is the right drug.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Alunbrig
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Alunbrig is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Alunbrig in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Alunbrig
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.